Trial record 1 of 450 for:    Century
Previous Study | Return to List | Next Study

Century Trial, a Randomized Lifestyle Modification Study for Management of Stable Coronary Artery Disease (Century)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT00756379
Recruitment Status : Recruiting
First Posted : September 22, 2008
Last Update Posted : November 3, 2016
Information provided by (Responsible Party):
K.Lance Gould, The University of Texas Health Science Center, Houston

Brief Summary:
The Century Trial is a single center Phase III randomized study sponsored by the Albert Weatherhead III Foundation and conducted by Dr. K. Lance Gould. The study hypothesis is that a combined image-treatment regimen of PET + comprehensive program of lifestyle modification and lipid lowering drugs to target lipid level will result in an improved cardiovascular risk score when compared to current standard optimal medical therapy, potentially resulting in a lower rate of death, non-fatal myocardial infarction (MI) and revascularization procedures during long term follow-up when compared with current standard of care. If our hypothesis is correct, we will not only improve our ability to prevent and treat CAD but we will also illustrate that, even with the expenses of behavioral interventions and imaging techniques, we can be very cost effective. This information may help patients at risk or with known CAD to obtain insurance coverage to prevent the disease as well as providing a more effective way of treating it.

Condition or disease Intervention/treatment Phase
Cardiovascular Disease Atherosclerosis Coronary Artery Disease Coronary Stenosis Other: Comprehensive therapy program for risk factor modification Phase 3

Detailed Description:

Advances in diagnostic imaging with expensive technologies and reimbursement policies that favor illness intervention rather than primary and secondary prevention have resulted in rising costs of health care and more people being deprived of its benefits (Sultz 2004, Bodenheimer 2002).

In the field of coronary artery disease (CAD) are several non-invasive imaging techniques for diagnostic and risk stratification purposes such as echocardiography, perfusion imaging (cardiac stress SPECT - single photon emission computed tomography - and stress PET - positron emission tomography), non-invasive cardiac computed tomography angiography (CTA) and combined perfusion-anatomy (PET-CT) studies. There are an estimated 40 million noninvasive cardiac tests performed each year (Mark DB 2003). For echocardiography and SPECT imaging, reimbursement from Medicare encompasses approximately 30% of all payments, totaling over $1 billion in the year 2000 (ACC 2003). There are, however, basic questions about cardiovascular imaging techniques that need to be addressed: how does technology benefit the patient? It is worth the cost? Is treatment plan enhanced? Is outcome better? Data are necessary for addressing these questions and if appropriate for acceptance among practicing physicians, patients and third party insurers.

The relevance of the proposed study, the CENTURY trial, lies in its original design, testing the impact of stress perfusion imaging by PET coupled with two different intensities of clinical management strategies (standard or comprehensive respectively). This study will examine post-test resource utilization and reduction of cardiovascular risk in patients with known disease or at high risk for CAD.

There will be a total of 1300 men and women enrolled with approximately 650 subjects randomized to one of two treatment arms. Eligible patients must have clinical indications for stress perfusion testing.

Following confirmation of eligibility and provision of signed informed consent, patients will be randomized to one of the two possible treatment strategies. At time of randomization patients will be assigned to "PET guided + comprehensive" versus "standard medical treatment."

Patients of both groups will have a baseline myocardial PET perfusion study to quantify the blood flow to the heart muscle, an electrocardiogram, an exercise treadmill stress test to assess exercise tolerance (fitness), a thorough review of the quality of their diet and a complete blood work covering individual lipid profiles. These tests and assessments will be repeated at 2 years and at 5 years.

In addition subjects assigned to the standard medical management arm will be managed by current standard care provided by their primary referring physician and will be asked to come for clinic study visits annually for 5 years to document their medical and lifestyle management. The PET scan results will be blinded until the end of the study to the standard of care management group.

Subjects enrolled in the comprehensive medical management arm will have the support of a team of professionals focusing on atherosclerotic risk factor modification that involves recommended treatment to target lipid levels, blood pressure and diabetes control, smoking cessation, very low fat diet and aerobic exercise program. This is in addition to standard current medical therapy as provided by the primary referring physician.

No experimental medication or procedures will be used. Clinic visits for subject's education and consulting in the comprehensive program will be performed five times during the first year and semiannually thereafter.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Randomized Trial of Comprehensive Lifestyle Modifications, Optimal Pharmacological Treatment and PET Imaging for Detection and Management of Stable Coronary Artery Disease
Study Start Date : March 2009
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : January 2019

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Intensive lifestyle modification
P.E.T. guided comprehensive therapy program. The study intervention is Comprehensive therapy program for risk factor modification. The Comprehensive program of atherosclerotic risk factor modification involves treatment to target lipid levels, blood pressure and diabetes control, smoking cessation, very low fat diet and aerobic exercise program. This is in addition to standard current medical therapy as provided by primary physician. No experimental medications or procedures will be used.
Other: Comprehensive therapy program for risk factor modification
Patients enrolled in the comprehensive therapy arm will have a baseline myocardial perfusion PET and the support of a team of professionals aiming to modify and minimize all the known CAD risk factors. During the 5 year follow-up they will be educated and guided toward a healthy lifestyle by a dietician, an exercise physiologist/cardiovascular physician specialist.
Other Names:
  • Coronary artery disease
  • Lifestyle management
  • Atherosclerosis
  • Cardiovascular disease management
  • Cardiovascular disease reversal
No Intervention: Current standard of care
Current standard of care medical management as provided by primary physician.

Primary Outcome Measures :
  1. 1.Clinical Endpoints-Average Risk Score modification during 5 year follow-up and major cardiovascular clinical events of death and non-fatal myocardial infarction. [ Time Frame: 2 years and 5 years ]

Secondary Outcome Measures :
  1. 2. Secondary outcome measures are major events consisting of death, non-fatal MI, stroke, and revascularization procedures. [ Time Frame: 2 years and 5 years ]

Other Outcome Measures:
  1. Comprehensive economic analysis to compare total cost and health outcomes of treating patients at risk or with established CAD [ Time Frame: 2 and 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must be competent to provide written informed consent.
  • Subjects must sign an Institutional Review Board (IRB) approved Informed Consent Form (ICF) and HIPAA Authorization prior to the initiation of any study procedures.
  • Men and women age ≥40

    _ Indication for stress perfusion testing

  • Appropriate Indications for stress perfusion testing:
  • Suspected CAD:
  • Men with any chest pain syndrome and two other risk factors
  • Women >50 years old with any chest pain syndrome and two other risk factors
  • Asymptomatic men and women >50 years with at least three other risk factors* or Coronary Calcium Agatston score >400.
  • Diabetic men and women and two other risk factors
  • Documented known CAD:
  • Men and women asymptomatic or stable symptoms and known CAD by abnormal catheterization or prior SPECT without revascularization after >2 years to evaluate worsening disease or
  • Men and women with worsening symptoms and known CAD by abnormal catheterization or prior SPECT/PET without revascularization
  • Men and women with chest pain syndrome and previous revascularization
  • Asymptomatic men and women >5 years after coronary artery bypass graft surgery (CABG) or >2 years after PCI

    • Risk factors: Diabetes, Current or recent cigarette smoking (within the last 12 months), LDL>130, low HDL <50 women, HDL <45 men, history of metabolic syndrome, hypertension (SPB>140), family history of premature (<60 year) CAD, Atherosclerotic carotid artery disease OR atherosclerotic peripheral vascular disease (APVD) as defined by ankle-brachial index below 0.9 and/or by abnormal duplex ultrasound, CT angiography, magnetic resonance angiography (MRA) or conventional invasive angiogram or previous revascularization procedure.

      • Framingham's high risk criteria refers to presence of diabetes mellitus with the limitation described above (c) or 10 year absolute Coronary Heart Disease(CHD)risk of >or= 20% (see tables Appendix A).

        • Chest pain is defined as Typical Angina if Exertional + Retrosternal + relieved with rest or sublingual nitroglycerin (NTG) , Atypical angina if only two of the above criteria are present and Non-anginal if one or none of the above are present.

Exclusion Criteria:

  • Age <40
  • Low pretest likelihood of CAD (= not meeting the above criteria)
  • Unstable angina high risk (dynamic ST-Twave ECG changes and/or elevated troponin)
  • Recent MI (<4 weeks)
  • Recent stroke (<4 weeks)
  • CABG or percutaneous coronary intervention (PCI) within the last 6 months
  • Severe renal dysfunction as defined by creatinine > 2.0 mg/dl
  • Active liver disease or hepatic dysfunction, AST or ALT > x 2 the upper limit of normal (ULN)
  • Concomitant valvular heart disease
  • Left ventricular ejection fraction (LVEF) <30%
  • Severe systemic hypertension defined as systolic blood pressure (SBP) > 200 mmHg
  • Symptomatic sustained or non-sustained ventricular tachycardia
  • Morbid Obesity defined by Body Mass Index > 35
  • Sever disability to prevent therapeutic exercise not expected to resolve within 6 months
  • Major non-cardiac co-morbidity limiting survival or social situation/condition that in the opinion of the investigator will preclude the patient from participation in the study follow-up.
  • Concurrent or prior (within last 30 days) participation in other research studies using investigational drugs or devices.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00756379

Contact: Catey V Carter, RN 713-500-5200
Contact: Mary P Haynie, RN, MBA 713-500-6611

United States, Texas
Weatherhead PET Center, Memorial Hermann Hospital TMC Recruiting
Houston, Texas, United States, 77030
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
Principal Investigator: K. Lance Gould, MD University of Texas Medical Health Science Center at Houston

Additional Information:
Responsible Party: K.Lance Gould, Professor, Internal Medicine, Cardiology, The University of Texas Health Science Center, Houston Identifier: NCT00756379     History of Changes
Other Study ID Numbers: HSC-MS-08-0312
First Posted: September 22, 2008    Key Record Dates
Last Update Posted: November 3, 2016
Last Verified: November 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by K.Lance Gould, The University of Texas Health Science Center, Houston:
Cardiovascular disease
Coronary artery disease
Coronary perfusion defect
Absolute coronary flow
Lifestyle management
Cardiovascular rehabilitation
Cardiovascular dietary guidelines

Additional relevant MeSH terms:
Cardiovascular Diseases
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Coronary Stenosis
Heart Diseases
Arterial Occlusive Diseases
Vascular Diseases